Compare Citius Pharmaceuticals Inc (CTXR) vs SMX Security Matters plc (SMX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs SMX Security Matters plc — how do they compare? Citius Pharmaceuticals Inc trades at $0.5 (market cap $13.62M), while SMX Security Matters plc trades at $3.8 (market cap $4.13M). The key difference: Citius Pharmaceuticals Inc is far larger — about 3.3× SMX Security Matters plc's market cap, and Citius Pharmaceuticals Inc is more actively traded (132,438 versus 124,362). Which is the better fit depends on your goals — on Pluang, investors hold Citius Pharmaceuticals Inc for 17 Days and SMX Security Matters plc for 21 Days on average.
| CTXR | SMX | |
|---|---|---|
Market Cap | $13.62M | $4.13M |
Volume | 132,438 | 124,362 |
Sector | Health | Industrials |
52-Week High | $1.82 | $74.08K |
52-Week Low | $0.48 | $3.79 |
Typical Hold Time | 17 Days | 21 Days |
Enterprise Value | $3.79M | -$27.20M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.5082, up 5.72% today, amid a bearish technical trend but with oversold oscillators suggesting potential for a near-term bounce. The company reported its first revenue of $7 million in 2026 from LYMPHIR sales, yet remains deeply unprofitable with a net income margin of -651.27%. Analyst consensus is strongly positive with five buy ratings and a $5.00 price target, highlighting optimism around its oncology drug launch despite significant cash burn from operations.
The outlook hinges on successful commercialization of LYMPHIR to offset steep losses. Investment opportunity lies in the drug's market adoption and analyst bullishness, but risks include sustained negative cash flow, execution challenges, and the stock's high volatility. Shareholder value depends on translating revenue growth into profitability.
SMX trades at $3.80, down 2.56% with a bearish technical outlook despite oversold RSI readings. The company shows severe financial distress with no revenue, negative EBITDA of -$130.44M, and deeply negative ROE of -819.22%. Recent news highlights SMX's digital material passport technology gaining media attention from Forbes, TIME, and Boston Herald in September-October 2026, focusing on recycled plastic verification and circular economy applications.
The stock faces substantial fundamental challenges with no current revenue generation and significant operating losses. While media coverage suggests technological potential in material verification, the absence of revenue and massive negative profitability metrics present extreme risk. Investment viability depends entirely on SMX's ability to monetize its technology platform amid ongoing cash burn.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About SMX Security Matters plc
SMX Security Matters plc is a digital authentication and tracking technology company that uses a chemical-based, invisible marker system to trace and verify products across global supply chains. Their technology creates a 'digital twin' of physical products, used for quality control, counterfeiting prevention, and ensuring sustainability compliance from raw materials to final sale. The company's solutions are applied across various industries, including precious materials, luxury goods, and fast-moving consumer goods.
Read more on SMX →
